| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.89% | -153.73% | -207.79% | 39.93% | 69.02% | 31.91% | 25.22% | 16.53% | 75.96% | — | — | — |
| Operating Margin | -11268.32% | -66772.17% | -10814.99% | -397.09% | -650.47% | -8696.70% | -13472.11% | -1717.20% | -231.05% | — | — | — |
| EBITDA Margin | -7418.23% | -43607.93% | -6825.98% | -259.77% | -306.61% | -8607.96% | -13282.52% | -1644.90% | -215.11% | — | — | — |
| Net Margin | -11897.04% | -71702.26% | -11276.98% | -397.96% | -654.04% | -8758.21% | -13479.65% | -1722.30% | -246.04% | — | — | — |
| Current Ratio | 1.06 | 1.10 | 1.85 | 1.15 | 0.07 | 0.07 | 0.59 | 1.78 | 1.14 | 0.21 | 0.07 | — |
| Quick Ratio | 0.78 | 1.06 | 1.72 | 0.91 | 0.07 | 0.07 | 0.59 | 1.78 | 1.13 | 0.19 | 0.07 | — |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -195.32% | -95.79% | -56.33% | -40.45% | -38.13% | 173.05% | 1009.24% | -183.36% | -131.13% | 82.72% | 110.56% | — |
| ROA | -70.77% | -51.57% | -43.25% | -37.74% | -9.53% | -557.31% | -265.04% | -91.46% | -26.91% | -144.81% | -445.30% | — |
| Asset Turnover | 0.01 | 0.00 | 0.00 | 0.09 | 0.01 | 0.06 | 0.02 | 0.05 | 0.11 | — | 0.00 | 0.00 |
| Book Value / Share | 1.77 | 1.63 | 5.97 | 8.65 | 0.09 | -0.02 | -0.00 | 0.02 | 0.02 | — | -0.02 | -0.00 |
Ainos Inc. is a dual-platform AI and biotech company focused on pioneering smelltech and immune therapeutics. Its smelltech platform, powered by AI Nose and a smell language model (SLM), digitizes scents into Smell ID, a machine-readable data format that enables intelligent sensing in robotics, smart factories, and healthcare applications. The company develops VELDONA®, a low-dose oral interferon therapy targeting rare, autoimmune, and infectious diseases, with active clinical programs in areas such as HIV-related oral warts, primary Sjögren’s syndrome, and feline chronic gingivostomatitis. Ainos Inc. also leverages proprietary sensor array technologies to advance healthcare AI and offers point-of-care testing devices, including antigen rapid test kits. These innovations position Ainos Inc. at the intersection of AI-driven diagnostics, scent digitization, and therapeutic solutions, serving medtech needs in diverse healthcare and technology sectors. Incorporated in 1984 and headquartered in the United States, Ainos Inc. continues to redefine machine perception through its integrated AI and biotech capabilities.